ATLANTA, Feb. 25, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial results for the fourth quarter and year ended December 31, 2010.
GeoVax reported a net loss of $478,784 for the fourth quarter ended December 31, 2010, as compared to a net loss of $843,275 for the comparable period in 2009. For the full year of 2010, the Company reported a net loss of $2,747,328 as compared to a net loss of $3,284,252 in 2009. Grant revenues were $5,185,257 and $3,668,195 for the years ended December 31, 2010 and 2009, respectively. As of December 31, 2010, the Company reported cash balances totaling $1,079,087. Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission before March 31, 2011.
Highlights of the Company's scientific and clinical progress during 2010 are as follows: Early results from the Phase 2a trial for the preventative version of GeoVax's vaccine indicated an excellent safety profile and highly reproducible immunogenicity. This trial was expanded to include testing of an additional, simpler vaccine regimen, and we expect patient enrollment and vaccinations to be completed during 2011. During 2010, GeoVax began recruiting and screening patients for a Phase 1/2 trial for the therapeutic version of our vaccine. In order to accelerate enrollment in this important study, a second site at the University of Alabama, Birmingham was recently added to complement the enrollment already underway in Atlanta. We reported preclinical results using GM-CSF (granulocyte/macrophage
Page: 1 2 3 4 5 6 Related biology technology :1
. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update2
. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program3
. GeoVax Presents Data at AIDS Vaccine 2008 Conference4
. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial5
. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update6
. GeoVax to Present at the BIO CEO & Investor Conference 20097
. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference8
. GeoVax Update Provided at the BIO CEO & Investor Conference 20099
. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results10
. GeoVax Labs, Inc. Announces First Quarter Financial Results11
. GeoVax to Exhibit at the 2009 BIO International Convention